Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

[en] The recent data reported by Tang and colleagues in Science Translational Medicine suggest that alpha-2 adrenoceptors (alpha2AAR) genetic heterogeneity may explain diverging results regarding the effects of alpha2AAR antagonists on insulin secretion and glucose control in patients with type 2 diabetes. They first confirmed that the risk variant for rs553668 (the A allele for a single-nucleotide polymorphism in ADRA2A) is likely to cause defective insulin secretion in human pancreatic islets. Second they showed that blocking alpha2AAR with yohimbine dose-dependently improves the reduced insulin secretion during an oral glucose tolerance test in patients with the risk variant. The successful translation of genomic information into clinical intervention in patients with type 2 diabetes provides proof of concept for the feasibility of individualized treatment based on genotype.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques

Language :

English

Title :

Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

Publication date :

2015

Journal title :

Annals of Translational Medicine

ISSN :

2305-5839

eISSN :

2305-5847

Publisher :

AME Publications, Hong Kong, China

Volume :

Issue :

Suppl 1

Pages :

S36

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 June 2015

Statistics

Number of views

63 (0 by ULiège)

Number of downloads

78 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383:1068-83.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.
Maruthur NM, Gribble MO, Bennett WL, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care 2014;37:876-86.
Scheen AJ. Personalising metformin therapy: a clinician's perspective.Lancet Diabetes Endocrinol. 2014;2:442-4.
Halban PA, Polonsky KS, Bowden DW, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014;37:1751-8.
Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007;56:2178-82.
Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-77.
't Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013;62:3275-81.
Schäfer SA, Tschritter O, Machicao F, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007;50:2443-50.
Robertson RP, Halter JB, Porte D Jr. A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 1976;57:791-5.
Abdel-Zaher AO, Ahmed IT, El-Koussi AD. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists. Pharmacol Res 2001;44:397-409.
Broadstone VL, Pfeifer MA, Bajaj V, et al. Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes 1987;36:932-7.
Ostenson CG, Pigon , Doxey JC, et al. Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes. J Clin Endocrinol Metab 1988;67:1054-9.
Tang Y, Axelsson AS, Spégel P, et al. Genotype-based treatment of type 2 diabetes with an a2A-adrenergic receptor antagonist. Sci Transl Med 2014;6:257ra139.
Rosengren AH, Jokubka R, Tojjar D, et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010;327:217-20.
Långberg EC, Seed Ahmed M, Efendic S, et al. Genetic association of adrenergic receptor alpha 2A with obesity and type 2 diabetes. Obesity (Silver Spring) 2013;21:1720-5.
Bo S, Cassader M, Cavallo-Perin P, et al. The rs553668 polymorphism of the ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study. Diabet Med 2012;29:549-52.
Ghimire LV, Muszkat M, Sofowora GG, et al. Variation in the a(2A) adrenoceptor gene and the effect of dexmedetomidine on plasma insulin and glucose.Pharmacogenet Genomics 2013;23:479-86.
Liggett SB. alpha2A-adrenergic receptors in the genetics, pathogenesis, and treatment of type 2 diabetes. Sci Transl Med 2009;1:12ps15.
Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011;12:1161-91.